PCN90 - Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

J Amdahl,A Wang,M Thabane,M Amonkar,T.E Delea

doi:10.1016/j.jval.2014.03.485

PCN90 - Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

J Amdahl, A Wang + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2014.03.485

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: May 1, 2014
Citations: 3	License type: publisher-specific-oa

Affiliation: Policy Analysis (United States), GlaxoSmithKline (Canada), GlaxoSmithKline (United States)

#Canadian Societal Perspective #Metastatic Melanoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCN90 - Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

Full Text